Evolus Stock (NASDAQ:EOLS)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$10.23

52W Range

$8.67 - $17.82

50D Avg

$12.84

200D Avg

$13.53

Market Cap

$642.86M

Avg Vol (3M)

$891.50K

Beta

0.97

Div Yield

-

EOLS Company Profile

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

332

IPO Date

Feb 08, 2018

Website

EOLS Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24	Dec 23	Dec 22
Service	$1.97M	$2.36M	$2.02M
Product	$264.31M	$199.72M	$146.59M

Fiscal year ends in Dec 24 | Currency in USD

EOLS Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$264.31M	$202.09M	$148.62M
Operating Income	$-34.41M	$-49.23M	$-57.58M
Net Income	$-50.42M	$-61.69M	$-74.41M
EBITDA	$-66.15M	$-41.81M	$-60.72M
Basic EPS	$-0.81	$-1.08	$-1.33
Diluted EPS	$-0.81	$-1.08	$-1.33

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 24Mar 04, 25 | 4:30 PM

Q3 24Nov 06, 24 | 4:30 PM

Q2 24Jul 31, 24 | 4:30 PM

Peer Comparison

Ticker	Company
PROC	Procaps Group S.A.
AMPH	Amphastar Pharmaceuticals, Inc.
PBH	Prestige Consumer Healthcare Inc.
ALKS	Alkermes plc
ITCI	Intra-Cellular Therapies, Inc.
SUPN	Supernus Pharmaceuticals, Inc.
ANIP	ANI Pharmaceuticals, Inc.
IXHL	Incannex Healthcare Limited
COLL	Collegium Pharmaceutical, Inc.
PAHC	Phibro Animal Health Corporation
PCRX	Pacira BioSciences, Inc.